Business Daily from THE HINDU group of publications
Wednesday, Apr 16, 2008
ePaper | Mobile/PDA Version | Audio


News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

Home Page - Pharmaceuticals
Markets - Open Offers
Open offer hopes buoy Orchid

Morgan Stanley buys shares through bulk deals


Our Bureau

Mumbai, April 15 The Orchid counter at both the NSE and the BSE saw heavy activity on Tuesday, as talks of a further stake buy by Solrex in the company started doing the rounds.

On the NSE, Orchid was amongst the most actively traded stocks.

While its total traded quantity being over three crore shares, its deliverable ratio was only 8.71 per cent.

(Deliverable ratio indicates the ratio of gross deliverable quantity across clients to the total number of shares traded in a scrip at the exchange.) The Orchid Chemicals stock shot up by over 16 per cent on both the NSE and BSE.

Open offer

“The surge in stock price seems to be due to the speculation that Solrex might buy more stake in Orchid Chemicals,” said Ms Sarabjit Kour Nangra, Analyst, Angel Broking Ltd.

Investors took new positions in anticipation that Ranbaxy group company Solrex might go in for an open offer, if it crossed the 15 per cent stake limit,” said an analyst.

The global financial major Morgan Stanley bought 3.30-lakh Orchid shares on the BSE and 4.2-lakh shares on the NSE through bulk deals on Tuesday.

In addition to this, the bulk deal data for the day showed heavy day-trading on the counter.

Solrex’s stake in Orchid inched closer to the 15 per cent mark, when last Friday, it added 3.29 per cent in Orchid through two bulk deals.

An analyst said that the recent stake buy by Solrex in Orchid does not seem like a pure financial investment.

“If it was simply a financial investment, why would they take their stake in Orchid so close to 15 per cent?” said the analyst. Ranbaxy Laboratories was Tuesday’s highest gainer in the BSE, with its price surging 8.62 per cent, on the back of its out-of court settlement with Anglo-Swedish drugmaker AstraZeneca in a patent-related dispute.

Ranbaxy Laboratories has 15.63 per cent weight in the Sensex.

In the recent past, Ranbaxy has picked up equity in Zenotech Laboratories Ltd, Krebs Biochemicals & Industries Ltd and Jupiter Bioscience Ltd. Krebs Biochemicals rose 19.96 per cent to Rs 64 on Tuesday.

Jupiter Biosciences rose by 3.51 per cent to Rs 157.95 and Zenotech Laboratories by 3.48 per cent to Rs 102.65.

More Stories on : Pharmaceuticals | Open Offers | Foreign Institutional Investors

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page



Clasic Hiring

Stories in this Section
Labour shortage hits wheat harvest operations


Air India sees drop in number of domestic passengers in first quarter
Deccan Aviation’s angel investors hit pay dirt
Government expects inflation to come down
Rupee to remain range-bound
Sector funds fare better than diversified funds
Short-term earnings upside for Aban Offshore
Ranbaxy settles patent issue with AstraZeneca
Ranbaxy: Nexium deal gives certainty
Open offer hopes buoy Orchid
RINL hikes steel price by Rs 6,000/t
HEG (Rs 293.25): Buy
Day Trading Guide
Infosys rides on growth in European operations
HCL Tech Q3 net revenue up; US biz healthy
Container train operators eye car transportation market
L&T to develop Bombay Dyeing complexes
HTL land sale plan hits hurdles
Unscathed so far, by US troubles
IT stocks gain, thanks to Infosys’ strong show
Commodity prices vulnerable


Smartbuy



The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2008, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line